Contrast-enhanced intraoperative ultrasound improved hepatic recurrence-free survival in initially unresectable colorectal cancer liver metastases

HuiFang Li,Ming Shi,Xingzhang Long,Pinzhu Huang,Chuan Peng,Wei He,Yuhong Li,Binkui Li,Yunfei Yuan,JiLiang Qiu,Ruhai Zou
DOI: https://doi.org/10.1016/j.dld.2024.09.009
IF: 5.165
2024-09-30
Digestive and Liver Disease
Abstract:Background We aimed to evaluate the role of Contrast-enhanced intraoperative ultrasound (CE-IOUS) with perfluorobutane microbubbles (Sonazoid) in improving the prognosis of patients with unresectable colorectal cancer liver metastases (CRLM). Methods A total of 130 Patients with unresectable CRLM who underwent curative hepatic resection at our institute were retrospectively analyzed. Of these 130 enrolled patients, 67 underwent intraoperative ultrasound alone (IOUS group); 63 underwent additional CE-IOUS and IOUS (CE-IOUS group). Normalized inverse probability treatment weighting (IPTW) was employed to balance baseline characteristics between groups. Hepatic recurrence-free survival (HRFS) and overall survival (OS) were compared. Results The treatment strategy was altered in 25 patients (25/63, 39.9%) due to the additional use of CE-IOUS. After applying IPTW, the CE-IOUS group exhibited a significantly lower rate of hepatic recurrence (hazard ratio [HR], 0.55; 95% confidence interval [CI] 0.32–0.95; P = 0.032). Subgroup analysis showed that CE-IOUS provided a significant benefit over IOUS in patients with bilobar liver metastases ( P = 0.007), or with a number of live tumors < 3 ( P = 0.021), or without DLM ( P = 0.018), or with extrahepatic metastasis ( P = 0.034), or with a minimum of 6 cycles of systemic therapy ( P = 0.03). Conclusions CE-IOUS is necessary for unresectable CRLM after preoperative chemotherapy, as it enhances detection accuracy and improves the prognosis of unresectable CRLM patients.
gastroenterology & hepatology
What problem does this paper attempt to address?